LENZ THERAPEUTICS INC (LENZ) — insider trading
Health Care · NASDAQ
LENZ THERAPEUTICS INC (LENZ) has 14 reported SEC Form 4 insider transactions in our data, including 3 open-market purchases among the most recent 14 (latest 2026-06-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Scheiner Zachary | Director | Grant / award / vesting (derivative) | 22,100 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Guerard Frederic | Director | Grant / award / vesting (derivative) | 22,100 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Thunen Shelley B | Director | Grant / award / vesting (derivative) | 22,100 | $0.00 | $0 | Form 4 |
| 2026-06-15 | MCCOLLUM JAMES W | Director | Grant / award / vesting (derivative) | 22,100 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Drapkin Kimberlee C | Director | Grant / award / vesting (derivative) | 22,100 | $0.00 | $0 | Form 4 |
| 2026-06-15 | George Jeffrey P. | Director | Grant / award / vesting (derivative) | 22,100 | $0.00 | $0 | Form 4 |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 22,100 | $0.00 | $0 | Form 4 |
| 2026-03-27 | Chevallard Daniel R. | Officer (Chief Financial Officer) | Open-market purchase | 7,500 | $8.57 | $64.3K | Form 4 |
| 2026-03-27 | Schimmelpennink Evert B. | Director, Officer (President, CEO and Secretary) | Open-market purchase | 28,089 | $8.95 | $251.4K | Form 4 |
| 2026-03-27 | George Jeffrey P. | Director | Open-market purchase | 5,592 | $8.92 | $49.9K | Form 4 |
| 2026-01-02 | Odrich Marc | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 14,000 | $0.00 | $0 | Form 4 |
| 2026-01-02 | Odrich Marc | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 84,200 | $0.00 | $0 | Form 4 |
| 2026-01-02 | Olsson Shawn | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 14,000 | $0.00 | $0 | Form 4 |
| 2026-01-02 | Olsson Shawn | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 84,200 | $0.00 | $0 | Form 4 |
Ask the chat about LENZ's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: LENZ THERAPEUTICS INC (LENZ).
Last updated 2026-06-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.